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formidable public health challenge.1 Steadily in-
creasing incidence rates, accompanied by disturbingCAPSULE SUMMARY
d Key articles in the melanoma
supplement are highlighted.
d The public health importance of
melanoma control, and this
supplement’s contribution to that effort,
are described.trends in melanoma mortal-
ity, have sparked a height-
ened commitment to early
detection and prevention.2
In that spirit, we welcome
the wealth of new informa-
tion captured in this supple-
ment.3 Found within are
some major studies that not
only clarify current under-
standing of melanoma trends
but also sharpen future strategies for public health
efforts. Of note, major studies in this monograph
broaden our understanding of melanoma epidemi-
ology and surveillance, risk behaviors, and interven-
tion strategies that advance the core public health
functions of assessment, assurance, and policy
development.3
Specifically, the broad range of topics addressed
in this monograph include: exposures that can lead
to the tumor (ultraviolet [UV] exposure); pathologic
aspects of the tumor (histology, staging, subsequent
primary cancers); surveillance (comprehensive ex-
amination of incidence rates, mortality, and survival;
surveys of sun-protection behaviors; and statewide
sun-protection programs); disease in specific popu-
lation subgroups (adolescents and young adults,
persons from low socioeconomic status areas, and
persons of different racial and ethnic groups); and
goals for reducing mortality (a strategic plan that
includes screening and education for individuals at
high risk).
To begin, the overriding initial goal remains to
maximize accurate cancer registry assessment of
melanoma incidence and mortality. In this regard,
the country has made substantial progress. Initially,
the traditional National Cancer Institute (NCI)
Surveillance, Epidemiology, and End Resultsthe US Department of Health and Human Services,
ashington, DC,a and Department of Society, Human Devel-
ment, and Health, Harvard School of Public Health, Boston.b
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e authors and do not necessarily reflect the opinions,database encompassed 5 states and 4 metropolitan
areas, or about 10% of the population. More recently,
Surveillance, Epidemiology, and End Results hasrecommendations, or offi
the Centers for Disease C
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0190-9622/$36.00expanded to include 9 states
and 6 metropolitan areas,
more than doubling cover-
age. Moreover, the growth of
the Centers for Disease
Control and Prevention
(CDC) National Program of
Cancer Registries (begun in
1992) now permits surveil-
lance of up to 96% of the
population. These two fed-eral systems, therefore, allow more comprehensive
analyses than ever before.
Along the way, comprehensive melanoma assess-
ment has encountered, and begun to overcome, the
problem of underreporting. A number of years ago,
studies began documenting melanoma underreport-
ing of incidence, ranging from 12% to 30% in cancer
registries.4-8 As the phenomenon appears largely
attributable to increasing care of patients with mel-
anoma outside the hospital setting, registries have
since embraced efforts to require reporting from
outpatient surgery centers, pathology facilities, and
doctors’ offices.
Two major studies in this supplement represent
major investigations of the national burden of mel-
anoma, while accounting for the biases introduced
by underreporting. In thorough analyses of national
data during a 15-year period, Watson et al9 and Jemal
et al10 document incidence increasing steadily from
1992 to 2006, the disproportionate burden on non-
Hispanic whites, and mortality that decreased in
younger (\65 years) populations but increased in
older ([65 years) ones. These insights raise appro-
priate public health questions about whether educa-
tion and early detection efforts have effectively
reached somepopulationsbutnotothers.Of concern,
studies in the monograph underscore the growingcial position of the journal editors or
ontrol and Prevention.
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groups suffer increased rates of advanced-stage mel-
anoma and decreased survival.10,11
Public health researchers have similarly made
substantial progress in tracking melanoma-related
risk behaviors. By integrating UVexposure questions
into national surveys (through the Health
Information National Trends Survey, the Behavioral
Risk Factor Surveillance System, and the National
Health and Nutritional Examination Survey), inves-
tigators note disturbing trends. For example, in this
monograph, Buller et al12 use Behavioral Risk Factor
Surveillance System data to document that in a given
year, one third of adults and over two thirds of
adolescents become sunburned.
Such results have prompted renewed efforts to
implement the public health functions of policy
development and assurance with respect to both
primary and secondary prevention. Regarding the
former, many agencies and entities are exploring
multiple ways to reduce intentional UV use. Sun-
protection teaching, led by the US Environmental
Protection Agency SunWise Program, now reaches
thousands of US schools13; pool-goers nationwide
can receive ‘‘Pool Cool’’ sun-safety teaching against
the backdrop of new protection policies.14 In 2009,
the World Health Organization International Agency
for Research on Cancer announced that it had placed
UV tanning beds into its highest cancer risk category:
‘‘carcinogenic to humans.’’15 This finding has led to
legislation related to tanning beds, which include
bans for all children in Germany and certain states in
Australia,16,17 restrictions for children in many US
states,18 and a new tax provision on indoor tanning
services in the 2010 Patient Protection and
Affordable Care Act.19 More countries and states
may seek legislative action in response to a recent
case-control study in Minnesota that found that more
than 60% of cases reported use of tanning beds, with
risk increasing by years and hours of use.20 Also, the
US Food and Drug Administration has recently
developed new rules for sunscreens that would
establish a standard testing protocol and address
UVA protection.21
Meanwhile, in this supplement, Townsend et al22
review the primary prevention strategy of integrating
CDC-funded sun-protection initiatives within state-
based comprehensive cancer control programs. Theyemphasize the need to tailor strategies to the local
context and recommend the use of cancer control
planning tools suchas theNCIP.L.A.N.E.T. (Plan, Link,
Act, Network with Evidence-based Tools).23
Related efforts also revolve around secondary
prevention initiatives of early detection and screen-
ing recommendations. Because evidence from ran-
domized trials is lacking, the US Preventive Services
Task Force (2009) does not endorse population-
based screening for skin cancer.24 However, al-
though not endorsing population-based screening,
the Institute of Medicine (2000) advised physicians to
be alert to the warning signs of melanoma in older
men.25 International studies from the United States,
Australia, and Germany add to the growing database
of screening trials that could inform future policy
discussions.26-28 Meanwhile, other studies explore
the potential value of self-screening and educational
programs to teach physicians how to integrate a
brief, skilled skin examination into routine exami-
nation, particularly in vulnerable groups.29-31
In summary, enhancing the early detection and
prevention of melanoma remains a national cancer
goal for our society. As most melanoma deaths
should be preventable, we need to continue to
maximize reporting; improve the status of behav-
ioral, educational, and screening trials; adopt effec-
tive policies that prevent sunburn through UV
protection; better understand the reasons for increas-
ing death rates in older populations; and align health
systems to facilitate prevention and early detection.
Meeting these targets and renewing our commitment
will lead to a healthier people for our country.32
REFERENCES
1. Koh HK. Melanoma screening: focusing the public health
journey. Arch Dermatol 2007;143:101-3.
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R,
Waldron W, et al, editors. SEER cancer statistics review,
1975-2007, National Cancer Institute. Bethesda (MD), based
on November 2009 SEER data submission, posted to the SEER
Web site, 2010. Available from: URL:http://seer.cancer.gov/csr/
1975_2007/. Accessed July 10, 2010.
3. Plescia M, Protzel Berman P, White MC. CDC Melanoma
surveillance in the United States. J Am Acad Dermatol 2011;
65:S1-2.
4. Koh HK, Clapp RW, Barnett JM, Nannery WM, Tahan SR, Geller
AC, et al. Systematic underreporting of cutaneous malignant
melanoma in Massachusetts: possible implications for national
incidence figures. J Am Acad Dermatol 1991;24:545-50.
5. Koh HK, Adame N, Geller AC, Clapp RW, Miller DR, Lew RA.
Cancer registry data on melanomas. N Engl J Med 1990;323:
921-2.
6. Cockburn M, Swetter SM, Peng D, Keegan TH, Deapen D,
Clarke CA. Melanoma underreporting: why does it happen,
how big is the problem, and how do we fix it? J Am Acad
Dermatol 2008;59:1081-5.
7. Merlino LA, Sullivan KJ, Whitaker DC, Lynch CF. The indepen-
dent pathology laboratory as a reporting source for cutaneous
J AM ACAD DERMATOL
NOVEMBER 2011
S3.e4 Koh and Gellermelanoma incidence in Iowa, 1977-1994. J Am Acad Dermatol
1997;37:578-85.
8. Karagas MR, Thomas DB, Roth GJ, Johnson LK, Weiss NS. The
effects of changes in health care delivery on the reported
incidence of cutaneous melanoma in western Washington
State. Am J Epidemiol 1991;133:58-62.
9. Watson M, Johnson CJ, Chen VW, Thomas CC, Weir HK,
Sherman R, et al. Melanoma surveillance in the United States:
overview of methods. J Am Acad Dermatol 2011;65:S6-16.
10. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J,
Kim J, et al. Recent trends in cutaneous melanoma incidence
and death rates in the United States, 1992-2006. J Am Acad
Dermatol 2011;65:S17-25.
11. Geller AC, Miller DR, Lew RA, Clapp RW, Wenneker MB, Koh HK.
Cutaneous melanoma mortality among the socioeconomically
disadvantaged in Massachusetts. Am J Public Health 1996;86:
538-43.
12. Buller DB, Cokkinides C, Hall HI, Hartman AM, Saraiya M,
Miller E, et al. Prevalence of sunburn, sun protection, and
indoor tanning behaviors among Americans: Review from
national surveys and case studies of 3 states. J Am Acad
Dermatol 2011;65:S114-23.
13. Kyle JW, Hammitt JK, Lim HW, Geller AC, Hall-Jordan LH,
Maibach EW, et al. Economic evaluation of the US Environ-
mental Protection Agency’s SunWise program: sun protection
education for young children. Pediatrics 2008;121:e1074-84.
14. Escoffery C, Glanz K, Hall D, Elliott T. A multi-method process
evaluation for a skin cancer prevention diffusion trial. Eval
Health Prof 2009;32:184-203.
15. International Agency for Research on Cancer. Sunbeds and UV
radiation. Available from: URL:http://www.iarc.fr/en/media-
centre/iarcnews/2009/sunbeds_uvradiation.php. Accessed July
12, 2011.
16. Skin Cancer Foundation. Tanning Beds: WHO issues official
warning. Available from: URL:http://www.skincancer.org/
tanning-beds-who-issues-official-warning.html. Accessed July
12, 2011.
17. Sun Smart. Available from: URL:http://www.sunsmart.com.au/.
Accessed July 12, 2011.
18. McLaughlin JA, Francis SO, Burkhardt DL, Dellavalle RP. Indoor
UV tanning youth access laws: update 2007. Arch Dermatol
2007;143:529-32.
19. Affordable Care Act of 2010: News releases, multimedia and legal
guidance. Available from: URL:http://www.tha.com/healthcare-
reform/public/2010/health-related-rev-ppaca.pdf. Accessed July
12, 2011.20. Lazovich D, Vogel RI, Berwick M, Weinstock MA, Anderson KE,
Warshaw EM. Indoor tanning and risk of melanoma: a
case-control study in a highly exposed population. Cancer
Epidemiol Biomarkers Prev 2010;19:1557-68.
21. New York Times. FDA unveils new rules about sunscreen
claims. Available from: URL:http://www.fda.gov/ForConsumers/
ConsumerUpdates/ucm049091.htm. Accessed July 12, 2011.
22. Townsend JS, Pinkerton B, McKenna SA, Higgins SM, Tai E,
Steele CB, et al. Targeting children through school-based
education and policy strategies: Comprehensive cancer con-
trol activities in melanoma prevention. J Am Acad Dermatol
2011;65:S104-13.
23. Cancer Control P.L.A.N.E.T. Available from: URL:http://cancer
controlplanet.cancer.gov/. Accessed July 12, 2011:65:S104-13
24. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of
the evidence for the US Preventive Services Task Force. Ann
Intern Med 2009;150:194-8.
25. Institute of Medicine. Extending Medicare coverage for pre-
vention and other services. Washington (DC): National Acad-
emy Press; 2000.
26. Geller AC, Sober AJ, Zhang Z, Brooks DR, Miller DR, Halpern A,
et al. Strategies for improving melanoma education and
screening for men age $ 50 years: findings from the
American Academy of Dermatological National Skin Cancer
Screening Program. Cancer 2002;95:1554-61.
27. Janda M, Lowe JB, Elwood M, Ring IT, Youl PH, Aitken JF. Do
centralized skin screening clinics increase participation in
melanoma screening (Australia)? Cancer Causes Control
2006;17:161-8.
28. Geller AC, Greinert R, Sinclair C, Weinstock MA, Aitken J,
Boniol M, et al. A nationwide population-based skin cancer
screening in Germany: proceedings of the first meeting of
the International Task Force on Skin Cancer Screening and
Prevention (September 24 and 25, 2009). Cancer Epidemiol
2010;34:355-8.
29. Weinstock MA, Martin RA, Risica PM, Berwick M, Lasater T,
Rakowski W, et al. Thorough skin examination for the early
detection of melanoma. Am J Prev Med 1999;17:169-75.
30. Gerbert B, Bronstone A, Maurer T, Berger T, McPhee SJ,
Caspers N. The effectiveness of an Internet-based tutorial in
improving primary care physicians’ skin cancer triage skills.
J Cancer Educ 2002;17:7-11.
31. Berwick M, Erdei E, Hay J. Melanoma epidemiology and public
health. Dermatol Clin 2009;27:205-14.
32. Koh HK. A 2020 vision for healthy people. N Engl J Med 2010;
362:1653-6.
